A Phase II study of isavuconazole prophylaxis in adult patients with AML/MDS and neutropenia
You are being asked to take part in this study because you have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and are about to begin treatment for the same. Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and their treatment may weaken your immune system and may make you more likely to develop invasive fungal infections (IFIs). The goal of this clinical research study is to learn if isavuconazole can help prevent invasive aspergillosis (IA) and other IFIs in patients with AML/MDS. The safety of this drug will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Isavuconazole Pro-Drug
Treatment Location: Only at MDACC
Sponsor: Astellas Pharma US, Inc.
IRB Review and Approval Date: 03/28/2017
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: